Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.
EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management
EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients
EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment
EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy
Now Viewing
EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
EP: 6.Evaluating Safety of Novel LDL Management Mechanism
EP: 7.Examining Results from VICTORION-INITIATE Trial
EP: 8.Other Notable Emerging Lipid-Lowering Treatments
EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents
EP: 10.Diabetes, GLP-1, and Lipid Reduction
EP: 11.Medication Adherence in Patients with High LDL Cholesterol
EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies
EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole
Recent Videos
Related Content
